BioSpace News Archive

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation (tACS) as an add-on treatment for the symptoms of major depressive disorder (MDD), also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep.

Synaptogenix, Inc. today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS).

ValGenesis successfully concluded ValConnect, its annual customer and partner conference, in Lisbon on Wednesday, June 19th, after hosting an impressive series of product announcements and customer success stories to customers, partners, and industry experts.

KindlyMD, Inc. (“KindlyMD” or the “Company”) (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, is pleased to announce its successful registration on SAM.gov, the official U.S. federal funding platform.

Pillar Clinical Research, a multi-specialty clinical research site network, has announced the appointment of Zach Mitchell as Chief Commercial Officer.

Actinogen Medical Limited announces the peer-reviewed publication of its phase 2a biomarker trial entitled “Plasma pTau181 Predicts Clinical Progression In A Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem for Mild Alzheimer’s Disease” in the 100th edition of the Journal of Alzheimer’s Disease.

HUADONG MEDICINE, through its wholly-owned subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO. LTD (Zhongmei HuaDong), has recently announced positive results from Phase I clinical trials of its innovative oral small molecule GLP-1 receptor agonist HDM1002 in China.

Neurophet announced that it presented research study on brain stimulation simulation related to Alzheimer’s disease at OHBM (Organization for Human Brain Mapping) Annual Meeting 2024.

Oramed Pharmaceuticals Inc. announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.